STOCK TITAN
  1. Home
  2. Sec-filings
  3. ALGS
  4. [Form 4] Aligos Therapeutics, Inc. Insider Trading Activity

Aligos Therapeutics (ALGS) CEO granted stock options for 105,840 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aligos Therapeutics, Inc. director and President & CEO Lawrence Blatt received a stock option grant covering 105,840 shares of common stock. The option has an exercise price of $7.03 per share and represents a right to buy, not a market purchase.

According to the vesting terms, 1/48th of the total shares vest in equal monthly installments starting on March 9, 2026, so the option becomes fully vested and exercisable on the fourth anniversary of that date, subject to his continued service. Following this award, he holds 105,840 stock option rights directly in this filing.

Positive

  • None.

Negative

  • None.

Insights

Routine CEO stock option grant with four-year monthly vesting schedule.

Lawrence Blatt, President & CEO of Aligos Therapeutics, received a grant of options for 105,840 shares of common stock at an exercise price of $7.03 per share. This is a compensation-related award, not an open‑market transaction.

The option vests in 48 equal monthly installments starting on March 9, 2026, reaching full vesting on the fourth anniversary of that date, contingent on continued service. There are no sales or exercises reported, and this filing shows only this derivative position, which is typical for long-term incentive alignment.

Insider BLATT LAWRENCE
Role President and CEO
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 105,840 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 105,840 shares (Direct)
Footnotes (1)
  1. F1. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did Aligos Therapeutics (ALGS) CEO Lawrence Blatt report in this Form 4?
Lawrence Blatt reported receiving a stock option grant for 105,840 shares of Aligos Therapeutics common stock. The option is a right to buy shares at a fixed exercise price of $7.03 per share, granted as part of his compensation package.

Is the Aligos Therapeutics (ALGS) Form 4 a stock purchase or sale by the CEO?
The Form 4 does not show a stock purchase or sale. It reports a compensation-related stock option grant, giving the CEO the right to buy 105,840 shares at $7.03 per share in the future, subject to vesting conditions.

What are the vesting terms of the 105,840 stock options granted to the ALGS CEO?
The 105,840 stock options vest in 48 equal monthly installments beginning on March 9, 2026. All shares become fully vested and exercisable on the fourth anniversary of that date, provided Lawrence Blatt continues to serve through each vesting date.

What is the exercise price and expiration date of the ALGS CEO stock option grant?
The stock option grant to the Aligos Therapeutics CEO has an exercise price of $7.03 per share. The option expires on March 9, 2036, giving a long time window in which vested portions may potentially be exercised.

How many derivative transactions are reported in this Aligos Therapeutics (ALGS) Form 4?
The Form 4 reports one derivative transaction: a stock option grant for 105,840 underlying shares of common stock. No exercises, sales, gifts, or tax-withholding dispositions are shown, indicating this is a straightforward equity award entry.

Does the Aligos Therapeutics (ALGS) Form 4 show any remaining option positions after the grant?
After the reported transaction, the filing shows 105,840 stock option rights held directly. The derivative position in this report consists solely of this grant, with no additional remaining option positions listed in the derivative summary.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BLATT LAWRENCE
(Last) (First) (Middle)
C/O ALIGOS THERAPEUTICS, INC.
1 CORPORATE DRIVE, 2ND FLOOR
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Aligos Therapeutics, Inc. [ ALGS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $7.03 03/09/2026 A 105,840 (1) 03/09/2036 Common Stock 105,840 $0 105,840 D
Explanation of Responses:
1. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
/s/ Lesley Ann Calhoun, as attorney-in fact for Lawrence M. Blatt 03/11/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR